



IN THE DISTRICT COURT OF CLEVELAND COUNTY
 STATE OF OKLAHOMA } S.S.
 CLEVELAND COUNTY }
 STATE OF OKLAHOMA }
 FILED FEB 28 2019

STATE OF OKLAHOMA, ex rel., MIKE HUNTER, ATTORNEY GENERAL
 OKLAHOMA, Case No. CJ-2017-816

Plaintiff,

In the office of the
 Court Clerk MARILYN WELLS

Honorable Thad Balkman

v.

PURDUE PHARMA L.P., et al.,

Defendants.

DEFENDANTS' MOTION FOR A CONTINUANCE

The Court needs to continue the pre-trial deadlines and trial date in this case to avoid the substantial prejudice caused by the State's discovery failings. A continuance is necessary to address this prejudice from the State's conduct. Yet it may still be possible, should the State meet its discovery obligations, to keep this case on track to be the first of the nation's opioid cases scheduled for trial even after a continuance, and Defendants propose exactly that.

Last Thursday the State produced 165,000 documents totaling almost *1.6 million pages*. To put this latest production in context, it doubles the total amount of information the State has provided—enough to fill approximately 450 bankers boxes—and it appears more is yet to come. For instance, within the last two days alone, the State has produced more than 8,500 pages of other documents—not including document productions that continue to be rolled out by the State as of the time of this writing.

Had Defendants received all of these documents months ago, when they were requested, we could have reviewed and used them to examine the State's fact and expert witnesses. We could also have provided them to our experts for consideration when forming their opinions in this case.

Now, however, that opportunity is lost under the Court's current schedule. Fact discovery will close March 15. Most of the State's witnesses have already been deposed, and the other depositions will happen without the benefit of meaningful review of these documents. At the same time, expert discovery is starting. Tomorrow, the Defendants' experts have to produce reports without the benefit of these newly produced documents, and then within days sit for depositions where they could be cross-examined with those same documents. Defendants must seek emergency relief from the deadline tomorrow as a result.

Maybe this massive 11th-hour production was the result of an oversight of monumental proportions, which begs the questions of whether the State and its private attorneys did their diligence before bringing this lawsuit, and why the State failed to find these documents sooner, despite repeated requests. Or maybe this was an intentional strategy of the State's private attorneys to protect their witnesses from difficult questions that would undermine the State's claims, or to play "gotcha" with Defendants' experts. Regardless, the prejudice to Defendants is plain, and it threatens the fairness and ultimate result of any trial.

Last week's avalanche is undoubtedly not the last of the State's last-minute discovery surprises. The State has been stonewalling discovery for much of the last year, forcing Defendants to file motion after motion, resulting in several orders to compel the State to produce discovery—orders that the State ignored. For instance, the Special Discovery Master's January 17, 2019 order compelled the State "to *complete* the required discovery and production on or before February 5, 2019" for a host of long-outstanding discovery requests. (Jan. 17, 2019 Hr'g Order at 7 (emphasis added).) It still has not happened: Among other examples, on February 22, 2019, Purdue catalogued in detail many of the State's outstanding discovery deficiencies, ranging from missing custodial files for prospective witnesses in many State agencies to defined

document categories – discovery sought many months ago in letters, motion practice, and Discovery Master Orders. (Feb. 22, 2019 Ltr. from E. Ryan to D. Pate (Ex. A).) The State did not respond.

The State believes it should recover billions of dollars for prescriptions that the Healthcare Authority authorized before they were dispensed, and that the Authority decided were medically necessary before they were reimbursed. Yet the State *still* has not produced key custodial files for Healthcare Authority employees who would be subject to deposition, several of whom have been requested since last October. (*Id.* at 2-3, 5-8.) Other documents categories from the Healthcare Authority are also still missing. (*Id.* at 9-10.) Do those missing documents show that the OHCA knowingly approved these prescriptions as medically necessary, which bars the State from now claiming they were improper? Or do the missing documents show that the OHCA violated federal law and knowingly approved as “medically necessary” prescriptions that were improper? Defendants do not know, because we just got these documents and need time to review them and then pose these questions to the State’s witnesses.

Similarly, only now are Defendants finally getting access to the State’s records that purportedly serve as the basis for the original and revised opinions of the State’s experts. How will the defense experts prepare responses that take into account this newly produced evidence, and prepare for their own depositions?

Finally, due to the State’s prior failure to produce timely expert reports that comply with the Oklahoma Rules and provide the basis for the experts’ opinions, Defendants are now faced with a compressed schedule for the parties to brief and this Court to consider the dispositive motions and *Daubert* challenges still to come. Under the current schedule, for example, Defendants will have to brief the challenges to the admissibility of the State’s experts before

their depositions are complete. Dispositive motions are due a day before the scheduled *Daubert* hearing. By the time the motions are fully briefed and the *Daubert* hearings concluded, the Court will have two weeks to consider and decide these critical and threshold legal issues, which may eliminate or narrow the issues and evidence to be presented at any trial.

These are real concerns that go to the heart of the fairness of this proceeding. A rush to trial has always been the favored strategy of the State's private attorneys, who have weaponized the discovery process and the expedited schedule, perhaps to pressure Defendants, and perhaps because they do not want evidence that would damage their case from coming to light. Either way, this is not even-handed justice.

The State will inevitably—and loudly—accuse Defendants of delay and cite their predictions about an eventual motion for continuance. Make no mistake: this motion is the result of the State's gamesmanship and discovery abuses. The State chose not to produce 1.6 million pages of responsive documents in response to timely discovery requests and Court orders from long ago. The State chose to make that production without explanation—literally days before the end of the discovery period—and without notice, despite numerous conferences and hearings, and near-daily efforts by Defendants to communicate about discovery. The State chose to produce those documents after the depositions of most State witnesses. Put simply, the State created the discovery problems that now require a continuance

Defendants therefore respectfully request a 100-day continuance of all pretrial dates other than the close of fact discovery, with the trial rescheduled to begin September 16. This is the minimum time required to further the requirements of fairness and due process, and it would still leave this as the first opioid case scheduled for trial. During this extended period, Defendants

should be afforded the opportunity to re-open necessary discovery against the State to the full extent warranted by the State's delinquent discovery responses.

ARGUMENT

Oklahoma law permits this Court to "continue [an] action at any stage of the proceedings upon terms as may be just." Okla. Stat. Ann. tit. 12, § 667. This statute aligns with the Court's inherent power to control its docket within sound discretion. *Boston v. Buchanan*, 2003 OK 114, 89 P.3d 1034, 1044 (citing *Hambright v. City of Cleveland*, 1960 OK 184, 360 P.2d 493, 496, *Kennedy v. District Court*, 121 Mont. 320, 194 P.2d 256, 264, 2 A.L.R.2d 1050 (1948)).

The mere desire to try a case fast is not an acceptable basis to deny a continuance that is necessary to protect the rights of the parties. For decades, the Supreme Court of Oklahoma has embraced this bedrock principle: "[W]hen a trial is forced with such dispatch as to result in depriving an interested party of reasonable opportunity to prepare for trial, and secure witnesses; and the whole circumstances are such as to convince that there was an abuse of judicial discretion, it is the duty of this court to reverse." *State v. Duerkson*, 1943 OK 6, 191 Okla. 670, 132 P.2d 649, 650. This is particularly true when the amount in controversy is "substantial and the case is quite important to all who are or may be interested." *Id.* The "chief test" when considering a continuance request is "whether the grant or denial of the motion operates in the furtherance of justice." *Id.*

The Supreme Court has also overruled a trial court's refusal to grant a continuance where a plaintiff's selective refusal to waive the doctor-patient privilege until trial allowed "plaintiff to present testimony of some doctors selected by him and close the mouth of another doctor he had consulted, who might contradict him." *Herbert v. Chicago, R.I. & P. R. Co.*, 1975 OK 160, 544 P.2d 898, 901. Indeed, the denial of a continuance will violate due process when it denies the

defendant the opportunity to “fully develop the facts” that are needed for a “full and complete hearing.” *Cent. State Cmty. Serv. v. Anderson*, 2012 OK CIV APP 110, ¶ 11, 292 P.3d 36, 39. The State’s massive, last minute productions have significantly prejudiced Defendants at a critical pretrial juncture, fewer than 90 days from the current start of trial –just three weeks before the close of fact discovery– and notably beyond the time when Defendants could serve any follow-up discovery implicated by the State’s productions, given the 30 days provided for responses. Defendants have no ability to review all of this material within the remaining discovery period, and certainly not by tomorrow, when defendants must disclose their experts’ opinions. Defendants have already lost the ability to use this evidence with most of the State’s witnesses. Within a matter of a few weeks, Defendants will also lose the opportunity to cross-examine the State’s experts with the very evidence upon which they relied—much of which is still being produced long after it was requested by Defendants, required by the Oklahoma Rules, and ordered by the Court, and some of which is still being withheld for no good reason.

For example, even after repeated motion practice and discovery orders, the State still refuses to produce key documents from the Oklahoma Employee Group Insurance Division (EGID). This is the agency that continues to list OxyContin as “clinically appropriate” and a “*preferred* brand-name medicine[.]” (HealthChoice Std. Medication List at 1 (Jan. 2019) (Ex. B) (emphasis added).) Yet EGID’s Chief Medical Officer testified that the State’s lawyers never asked him for documents, (Lawler Dep. (Ex. C) at 144:5-11), despite Defendants’ months-long requests for his custodial file. Even worse, the State’s lawyers never told the Chief Medical Officer to preserve documents until just two or three months ago. (*Id.* at 145:15-20.) This

testimony reveals that the State has not been attending to even basic discovery duties, and this failure may have led to spoliation of evidence.¹

As another example, when the State de-identified its claims data to remove patient and physician information, it superimposed anonymized codes in the complex data productions that do not correspond to one another (as the patient and physician information would). This resulted in another emergency motion by Defendants. (Defs' Emergency Mot. to Compel, filed Feb. 12, 2019.) On February 18, 2019, Special Master Hetherington ordered the State to correct these and other defects in their database productions, but not until March 1. (Feb. 18, 2019 Hr'g Order at 4.) That is just two weeks before the close of discovery, the day expert disclosures are due, and almost 14 months after Defendants requested the data.

Also consider Defendants' expert disclosures, which are due tomorrow. The experts have no chance to review the 1.6 million pages of documents just produced, so any disclosure will not be able to take that information into account. The experts also will not have the advantage of the numerous documents the State continues to withhold, even though Defendants requested them repeatedly, and the Court ordered the State to produce them. Because of this, the defense experts may also be open to unfair criticism from the State's lawyers.

The prejudice does not end with the close of expert discovery. Due to the State's failure to comply with the expert disclosure deadline, the Court had to substantially shift the timing for expert disclosures and extend the time for expert depositions. At the same time, the trial date remains unchanged, thereby compressing and overlapping the parties' and the Court's work on

¹ In the interest of full disclosure, Purdue also notes that it recently learned a (former) discovery vendor did not properly process approximately less than 1.0% of Purdue's documents, totaling about 51,000 documents, which led to their production in some instances without track changes or comment bubbles. In the coming days, Purdue is remedying this technical glitch with a corrected production.


Daubert and summary judgment issues Defendants will have to brief *Daubert* before the end of expert discovery and will simultaneously have to brief dispositive motions, which are due just one day after the *Daubert* hearing. The *Daubert* issues will be far from simple, for the State's unqualified experts use unprecedented theories to claim billions of dollars in state entitlements for routine state expenditures never before claimed by the State. By the time dispositive motions are fully briefed, the Court will have only two weeks to consider them. Perhaps by then it will be apparent to the Court that the State has no case at all. But at a minimum, the dispositive and other pretrial motions surely will narrow the evidence and issues appropriate for trial. In the interest of efficiency, fairness, and to ensure an adequate appellate record, the Court should leave itself time to give these motions the consideration they are due.

CONCLUSION

This is an important case for all parties and for Oklahomans. So it is also important to do this right—to allow Defendants the opportunity to prepare a defense that accounts for the massive amounts of information just produced, and the additional information sure to come in the next two weeks. A continuance serves the interests of justice and results in a relatively short delay. The alternative is a fundamentally unfair pretrial process that is destined to end in an equally unfair trial. Defendants respectfully submit that this Court should grant the request for a continuance and extend all deadlines apart from the close of fact discovery by 100 days.

Date: February 28, 2019

Respectfully submitted,



Sanford C. Coats, OBA No. 18268
Joshua D. Burns, OBA No. 32967
CROWE & DUNLEVY, P.C.
Braniff Building
324 N. Robinson Ave., Ste. 100
Oklahoma City, OK 73102
Tel: (405) 235-7700
Fax: (405) 272-5269
sandy.coats@crowedunlevy.com
joshua.burns@crowedunlevy.com

Of Counsel:

Sheila Birnbaum
Mark S. Cheffo
Hayden A. Coleman
Paul A. LaFata
Jonathan S. Tam
DECHERT, LLP
Three Bryant Park
1095 Avenue of the Americas
New York, New York 10036
Tel: (212) 698-3500
Fax: (212) 698-3599
sheila.birnbaum@dechert.com
mark.cheffo@dechert.com
hayden.coleman@dechert.com
paul.lafata@dechert.com
jonathan.tam@dechert.com

Eric Wolf Pinker
John Thomas Cox III
Lynn Pinker Cox & Hurst, LLP
2100 Ross Avenue, Suite 2700
Dallas, TX 75201
epinker@lynnllp.com
tcox@lynnllp.com

*Counsel for Purdue Pharma L.P.,
Purdue Pharma Inc., and The Purdue
Frederick Company Inc.*

CERTIFICATE OF SERVICE

I hereby certify that on February 28, 2019, I caused a true and correct copy of the following:

DEFENDANTS' MOTION FOR A CONTINUANCE

to be served via email upon the counsel of record listed on the attached Service List.

A handwritten signature in black ink, consisting of several stylized, cursive letters, is written above a horizontal line. The signature appears to be "R. D. S." or similar.

SERVICE LIST

WHITTEN BURRAGE

Michael Burrage
Reggie Whitten
512 N. Broadway Avenue, Suite 300
Oklahoma City, OK 73102
mburrage@whittenburrage.com
rwhitten@whittenburrage.com

*Counsel for Plaintiff the State of
Oklahoma*

OKLAHOMA OFFICE OF THE ATTORNEY GENERAL

Mike Hunter
Abby Dillsaver
Ethan A. Shaner
313 NE 21st St
Oklahoma City, OK 73105
abby.dillsaver@oag.ok.gov
ethan.shaner@oag.ok.gov

Counsel for Plaintiff the State of Oklahoma

NIX, PATTERSON & ROACH, LLP

Bradley E. Beckworth
Jeffrey J. Angelovich
Lloyd "Trey" Nolan Duck, III
Andrew Pate
Lisa Baldwin
Nathan B. Hall
512 N. Broadway Ave., Suite 200
Oklahoma City, OK 73102
bbeckworth@nixlaw.com
jangelovich@npraustin.com
tduck@nixlaw.com
dpate@nixlaw.com
lbaldwin@nixlaw.com
nhall@nixlaw.com

Counsel for Plaintiff the State of Oklahoma

GLENN COFFEE & ASSOCIATES, PLLC

Glenn Coffee
915 N. Robinson Ave.
Oklahoma City, OK 73102
gcoffee@glenncoffee.com

Counsel for Plaintiff the State of Oklahoma

ODOM, SPARKS & JONES PLLC

Benjamin H. Odom
John H. Sparks
Michael W. Ridgeway
David L. Kinney
HiPoint Office Building
2500 McGee Drive Ste. 140
Oklahoma City, OK 73072
odomb@odomsparks.com
sparksj@odomsparks.com
ridgewaym@odomsparks.com
kinneyd@odomsparks.com
*Counsel for Defendants Janssen
Pharmaceuticals, Inc., Johnson & Johnson,
Janssen Pharmaceutica, Inc. n/k/a Janssen
Pharmaceuticals, Inc., and Ortho-McNeil-*

FOLIART, HUFF, OTTAWAY & BOTTOM

Larry D. Ottaway
Amy Sherry Fischer
201 Robert S. Kerr Avenue, 12th Floor
Oklahoma City, OK 73102
larryottaway@oklahomacounsel.com
amyfischer@oklahomacounsel.com
*Attorneys for Defendants Johnson & Johnson,
Janssen Pharmaceuticals, Inc., Janssen
Pharmaceutica, Inc. n/k/a Janssen
Pharmaceuticals, Inc., and Ortho-McNeil-
Janssen Pharmaceuticals, Inc. n/k/a Janssen
Pharmaceuticals, Inc and Ortho-McNeil-
Janssen Pharmaceuticals, Inc. n/k/a Janssen
Pharmaceuticals, Inc.*

Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.

O'MELVENY & MYERS LLP

Stephen D. Brody
David K. Roberts
1625 Eye Street NW
Washington, DC 20006
sbrody@omm.com
droberts2@omm.com

Counsel for Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.

DECHERT, LLP

Sheila Birnbaum
Mark S. Cheffo
Hayden A. Coleman
Paul A. LaFata
Jonathan S. Tam
Erik Snapp
Three Bryant Park
1095 Avenue of the Americas
New York, New York 10036
sheila.birnbaum@dechert.com
mark.cheffo@dechert.com
hayden.coleman@dechert.com
paul.lafata@dechert.com
jonathan.tam@dechert.com
erik.snapp@dechert.com

*Counsel for Purdue Pharma L.P.,
Purdue Pharma Inc. and The Purdue
Frederick Company Inc.*

O'MELVENY & MYERS LLP

Charles C. Lifland
Jennifer D. Cardelús
400 S. Hope Street
Los Angeles, CA 90071
clifland@omm.com
jcardelus@omm.com

Counsel for Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.

LYNN PINKER COX & HURST, LLP

Eric Wolf Pinker
John Thomas Cox III
Lynn Pinker Cox & Hurst, LLP
2100 Ross Avenue, Suite 2700
Dallas, TX 75201
epinker@lynnllp.com
tcox@lynnllp.com

*Counsel for Purdue Pharma L.P.,
Purdue Pharma Inc. and The Purdue
Frederick Company Inc.*

GABLEGOTWALS

Robert G. McCampbell

Nicholas V. Merkley

Ashley E. Quinn

One Leadership Square, 15th Fl.

211 North Robinson

Oklahoma City, OK 73102-7255

RMcCampbell@Gablelaw.com

NMerkley@Gablelaw.com

AQuinn@Gablelaw.com

Attorneys for Defendants Cephalon, Inc., Teva

Pharmaceuticals USA, Inc., Watson

Laboratories, Inc., Actavis LLC, and Actavis

Pharma, Inc. f/k/a/ Watson Pharma, Inc.

MORGAN, LEWIS & BOCKIUS LLP

Steven A. Reed

Harvey Bartle IV

Rebecca Hillyer

Lindsey T. Mills

1701 Market Street

Philadelphia, PA 19103-2921

steven.reed@morganlewis.com

harvey.bartle@morganlewis.com

rebeccahillyer@morganlewis.com

lindsey.mills@morganlewis.com

Attorneys for Defendants Cephalon, Inc., Teva

Pharmaceuticals USA, Inc., Watson

Laboratories, Inc., Actavis LLC, and Actavis

Pharma, Inc. f/k/a/ Watson Pharma, Inc.

MORGAN, LEWIS & BOCKIUS LLP

Brian M. Ercole

200 S. Biscayne Blvd., Suite 5300

Miami, FL 33131

brian.ercole@morganlewis.com

Attorneys for Defendants Cephalon, Inc., Teva

Pharmaceuticals USA, Inc., Watson

Laboratories, Inc., Actavis LLC, and Actavis

Pharma, Inc. f/k/a/ Watson Pharma, Inc.

EXHIBIT A

LYNN PINKER COX HURST

ELIZABETH RYAN
Partner

D 214 981 3821
F 214 981 3839
eryan@lynnllp.com

Lynn Pinker Cox & Hurst, LLP
2100 Ross Avenue
Suite 2700
Dallas, Texas 75201
lynnllp.com

February 22, 2019

Mr. Drew Pate
NIX PATTERSON, LLP
3600 North Capital of Texas Highway
Building B, Suite 350
Austin, Texas 78746

Re: Deficiencies in the State's Document Production in *State of Oklahoma v. Purdue Pharma L.P., et al.*, Case No. CJ-2017-816, pending in the District Court of Cleveland County, Oklahoma

Dear Drew:

I write to follow up on (1) my January 23, 2019 e-mail to you regarding the State's failure to produce requested custodial files; (2) the January 24, 2019 conference call that you, Trey Cox, and I had regarding fact witness depositions and custodial file productions; (3) my February 1, 2019 letter to you regarding the State's failure to provide deposition dates and custodial files for multiple witnesses; and (4) my February 14, 2019 e-mail to you requesting deposition dates, custodial files, and various other previously requested documents the State has failed to produce. I have addressed each of the outstanding issues for which we need immediate responses from the State below.

A. Repeatedly Requested Custodial Files that the State Has Not Yet Produced

Purdue has repeatedly requested the files from the State for the following custodians. I have included the dates of Purdue's requests below. The State has not yet produced files from these custodians. Note that while you have told me that your firm does not represent a few of the individuals on this list, that does not obviate the State of its obligation to gather responsive documents from these custodians. Furthermore, many of these custodians are deponents in this case and the Court has ordered the State to produce files from deponents in advance of depositions. (*See* 10/18/2018 Order on Purdue's Mot. to Compel Custodial Files in Advance of Depos.; 12/26/2018 Order on Purdue's Motion to Compel.) The State has not complied with those orders. Please

Mr. Drew Pate
 NIX PATTERSON, LLP
 February 22, 2019

Page 2

produce all responsive documents that are in the following individuals' possession, custody, and control by 5:00 p.m. Central Time on March 1, 2019.

Custodian	State Agency	Dates Purdue Requested Files
Becky Pasternik-Ikard	Health Care Authority	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Bob Ricks	State Bureau of Investigation	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Carrie Daniels	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Carrie Evans	Oklahoma Health Care Authority	12/18/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Carrie Slatton-Hodges	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Christopher Shearer	Osteopathic Association; Opioid Overdose Fatality Review Board	02/14/2019 E-mail
Claire Nguyen	State Department of Health	01/21/2019 Letter 02/15/2019 E-mail
Darrell Weaver	Bureau of Narcotics & Dangerous Drugs Control	01/14/2018 E-mail
Deborah Bruce	Board of Osteopathic Examiners	10/30/2018 Letter

Mr. Drew Pate
 NIX PATTERSON, LLP
 February 22, 2019

Page 3

Custodian	State Agency	Dates Purdue Requested Files
		11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Diana O'Neal	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Don Vogt	Bureau of Narcotics & Dangerous Drugs Control	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Drew Edmondson	Former Attorney General	12/10/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Durand Crosby	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Ed Lake	Department of Human Services; Opioid Overdose Fatality Review Board	02/14/2019 E-mail
Ed Long	Health Care Authority	12/18/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Ellen Buettner	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter

Mr. Drew Pate
 NIX PATTERSON, LLP
 February 22, 2019

Page 4

Custodian	State Agency	Dates Purdue Requested Files
		02/14/2019 E-mail
Ferris Barger	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Frank Lawler	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Frank Wilson	Office of Management & Enterprise Services	10/30/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Jason Beaman	Oklahoma State University Center for Health Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Jean Hausheer	State Medical Association; Opioid Overdose Fatality Review Board	02/14/2019 E-mail
Jessica Hawkins	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Jill Geiger	Office of State Finance	02/01/2019 02/14/2019
John Scully	Bureau of Narcotics & Dangerous Drugs Control	02/01/2019 Letter 02/14/2019 E-mail

Mr. Drew Pate
 NIX PATTERSON, LLP
 February 22, 2019

Page 5

Custodian	State Agency	Dates Purdue Requested Files
Kevin Taubman	Opioid Overdose Fatality Review Board	02/14/2019 E-mail
Liz Massey	Board of Nursing	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Lyle Kesley	Medical Board	02/01/2019 Letter 02/14/2019 E-mail
Lynn Mitchell	State Department of Health; Employees Group Insurance Division Board; Health Care Authority	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Lynne Bajema	Office of Management & Enterprise Services	02/01/2019 Letter 02/14/2019 E-mail
Mark Liotta	Workers' Compensation Commission	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Mark Reynolds	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Mark St. Cyr	State Board of Pharmacy	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Mark Stewart	Bureau of Narcotics and Dangerous Drugs Control	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail

Mr. Drew Pate
 NIX PATTERSON, LLP
 February 22, 2019

Page 6

<u>Custodian</u>	<u>State Agency</u>	<u>Dates Purdue Requested Files</u>
Mark Woodward	Bureau of Narcotics & Dangerous Drugs Control	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Mary Fallin	Former Governor	12/10/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Mike Fogarty	Health Care Authority	02/14/2019 E-mail
Mike Hunter	Attorney General	12/10/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Nichole King	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Patricia Sommer	Workers' Compensation Commission	11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Paul King	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Reji Varghese	Board of Medical Licensure & Supervision	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Rick Adams	State Bureau of Investigation	02/01/2019 Letter 02/14/2019 E-mail
Scott Pruitt	Former Attorney General	12/10/2018 Letter 02/01/2019 Letter

Mr. Drew Pate
 NIX PATTERSON, LLP
 February 22, 2019

Page 7

Custodian	State Agency	Dates Purdue Requested Files
		02/14/2019 E-mail
Stephanie U'ren	State Department of Health	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 02/01/2019 Letter 02/14/2019 E-mail
Steven Buck	Office of Juvenile Affairs	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Steven Crawford	Oklahoma Health Care Authority	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call
Steven Montgomery	Employees Group Insurance Division Board	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Susan Rogers	State Dental Board; Bureau of Narcotics and Dangerous Drugs Control	10/30/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Sylvia Lopez	Health Care Authority	12/18/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Terri White	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail

Custodian	State Agency	Dates Purdue Requested Files
Theresa South	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Tom Bates	Former Assistant State Attorney General	02/14/2019 E-mail
Travis Tate	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Vickie Kersey	Oklahoma Health Care Authority	12/18/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail

B. Responsive Documents that the State Has Not Produced

In addition to files from the relevant custodians identified above, the State has not produced the following documents or categories of documents, which are responsive to Purdue’s document requests, including document requests that were the subject of (1) the Court’s order from April 25, 2018 compelling production; and (2) the Court’s order from the January 17, 2019 hearing, which required the State to produce responsive documents by February 5, 2019. The State has not fully complied with those orders. Accordingly, please produce these documents by 5:00 p.m. Central Time on March 1, 2019.

Document or Category of Documents	Notes
Oklahoma Department of Public Safety documents	The Court ordered production on October 4, 2018. The State has not produced these documents.
Oklahoma Drug Threat Assessments	The State has produced only the 2017 report. Purdue reminded the State to produce these

Document or Category of Documents	Notes
	responsive documents on January 7, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 3, 6, and 8.
Medical examiner summaries relied upon in compiling statistics related to overdose deaths in Oklahoma.	Purdue reminded the State to produce these responsive documents on January 21, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 3 and 6.
Dr. Burl Beasley's February 5, 2019 presentation at the Medicaid Innovations Forum in Orlando, Florida, as well as any drafts or related documents.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.
Dr. Burl Beasley's Spring 2018 presentations to the Board of Pharmacy in Oklahoma City and Tulsa, as well as any drafts or related documents.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.
Dr. Burl Beasley's presentation to the Oklahoma Health Care Authority related to the estimated cost of implementing an electronic records system, as well as any drafts or related documents.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production No. 5.
All contracts between the Oklahoma Health Care Authority and Pharmacy Management Consultants, including all proposals and RFIs from Pharmacy Management Consultants and other interested vendors that were received in connection with those contracts.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production No. 3 and Purdue Frederick's First Requests for Production No. 3.
All documents related to the Oklahoma Health Care Authority's audit of compounded topical medications and subsequent determination to	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are

Document or Category of Documents	Notes
cease coverage and reimbursement for those medications.	responsive to Purdue Pharma LP's First Requests for Production No. 6 and Purdue Pharma Inc.'s First Requests for Production No. 4.
All documents related to the Oklahoma Health Care Authority's ongoing initiative to review Pharmacy Management Consultants' processing of prior authorizations.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Frederick's First Requests for Production Nos. 5, 6, and 7, and Purdue Pharma Inc.'s First Requests for Production Nos. 2 and 3.
Mandatory quarterly reports for the Centers for Disease Control on opioid prescribing statistics, including statistics on high prescribers, doctor shoppers, PDMP alters on conflicting and dangerous prescriptions, none of which contain individualized patient data.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 3, 6, and 8.
Oklahoma Bureau of Narcotics & Dangerous Drugs Control's diversion reports.	The State has only produced the 2006-2007 report. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 3, 6, and 8.
All minutes of meetings of the Oklahoma Board of Dentistry during which opioid medications or diversion of prescription drugs were discussed.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.
All communications from the Oklahoma Board of Dentistry or its officers addressing draft or proposed legislation related to opioids.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production No. 6.
All meetings of minutes for the Drug Utilization Review Board during which opioid medications, diversion of prescription drugs, addiction to prescription drugs, or Medicaid fraud were discussed.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 2, 6, and 8.

Document or Category of Documents	Notes
All Drug Utilization Review Board Reports.	The State has produced very few of the existing reports. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 2, 6, and 8.
Documents within the possession, custody, or control of Employee's Group Insurance Department and the Office of Management and Enterprise Services.	The State has produced only 68 documents from Employee's Group Insurance Department. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8 and Purdue Frederick's First Requests for Production Nos. 5, 6, and 7.
Oklahoma Bureau of Narcotics and Dangerous Drugs' PowerPoints and public education presentations, including drafts, regarding prescription drugs or opioids.	Mark Woodward testified that he has approximately 24 years of presentations in his possession, which the State has not produced. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.
The meeting minutes from any State-sponsored or State-formed group or commission related to opioids, including but not limited to the minutes from the meetings of the groups that met to discuss the opioid prescribing guidelines.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.

C. The State's February 21, 2019 Productions


Finally, I note that yesterday, the State produced documents through approximately sixty-three separate production e-mails and links. Purdue is beginning its review of that production. If you contend the State's most recent production satisfied the State's production obligations that I have addressed here, then please provide me the Bates label ranges for the responsive custodial files, documents, or categories of documents.

Mr. Drew Pate
NIX PATTERSON, LLP
February 22, 2019

Page 12

Please contact me if you have any questions.

Thank you,

A handwritten signature in black ink, appearing to read "Elizabeth Yvonne Ryan". The signature is fluid and cursive, with a large initial "E" and "R".

Elizabeth Yvonne Ryan

EYR:as

EXHIBIT B

HealthChoice Standard Medication List

The HealthChoice Standard Medication List is a guide within select therapeutic categories for clients, plan members and health care providers. **Generics should be considered the first line of prescribing.** If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase *Italics*, and generic products in lowercase *italics*.

PLAN MEMBER

HealthChoice provides you with prescription benefits administered by CVS Caremark®. Ask your doctor to consider prescribing, when medically appropriate, a preferred medicine from this list. Take this list along when you or a covered family member sees a doctor.

Please note:

- Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the U.S. Food and Drug Administration (FDA) may not be covered upon release to the market.
- You may be responsible for the full cost of non-formulary products that are removed from coverage.
- For specific information regarding your prescription benefit coverage and copay¹ information, please visit www.caremark.com or contact a CVS Caremark Customer Care representative at 1-877-720-9375. If you have a hearing impairment and need telecommunications device (TDD) assistance, please dial 1-800-863-5488.
- CVS Caremark may contact your doctor after receiving your prescription to request consideration of a drug list product or generic equivalent. This may result in your doctor prescribing, when medically appropriate, a different brand-name product or generic equivalent in place of your original prescription.
- In most instances, a brand-name drug for which a generic product becomes available will be designated as a non-preferred option upon release of the generic product to the market.

HEALTH CARE PROVIDER

Your patient is covered under HealthChoice prescription benefits administered by CVS Caremark. As a way to help manage health care costs, we encourage you to authorize generic substitutions whenever possible. If you believe a brand-name product is necessary, consider prescribing a brand-name product on this list.

Please note:

- Generics should be considered the first line of prescribing.
- This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. HealthChoice prescription benefits may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the FDA may not be covered upon release to the market.
- HealthChoice may have a different copay¹ for specific products on the list.
- Unless specifically indicated, drug list products will include all dosage forms.
- Log on to www.caremark.com to check coverage and copay¹ information for a specific medicine.

ANALGESICS

§ NSAIDs

diclofenac sodium
meloxicam
naproxen

§ NSAIDs, COMBINATIONS

diclofenac sodium-
misoprostol

§ NSAIDs, TOPICAL

diclofenac sodium gel 1%
diclofenac sodium solution

§ COX-2 INHIBITORS

celecoxib

§ GOUT

allopurinol
colchicine tablet
probenecid
COLCRYS

ULORIC

§ OPIOID ANALGESICS

codeine-acetaminophen
fentanyl transdermal
fentanyl transmucosal
lozenge

hydrocodone-acetaminophen

hydromorphone

hydromorphone ext-rel

methadone

morphine

morphine ext-rel

morphine suppository

oxycodone

oxycodone-acetaminophen

tramadol

tramadol ext-rel

ABSTRAL

BELBUCA

BUTRANS

EMBEDA

HYSINGLA ER

NUCYNTA

NUCYNTA ER

OXYCONTIN

SUBSYS

ANTI-INFECTIVES

ANTIBACTERIALS

§ CEPHALOSPORINS

cefdinir

cefprozil

cefuroxime axetil

cephalexin

SUPRAX

§ ERYTHROMYCINS /

MACROLIDES

azithromycin

clarithromycin

clarithromycin ext-rel

erythromycins

DIFICID

§ FLUOROQUINOLONES

ciprofloxacin

ciprofloxacin ext-rel

levofloxacin

moxifloxacin

§ PENICILLINS

amoxicillin

amoxicillin-clavulanate

dicloxacillin

penicillin VK

§ TETRACYCLINES

doxycycline hyclate

minocycline

tetracycline

§ ANTIFUNGALS

fluconazole

itraconazole

terbinafine tablet

ANTIVIRALS

§ CYTOMEGALOVIRUS AGENTS

valganciclovir

§ HERPES AGENTS

acyclovir

valacyclovir

§ INFLUENZA AGENTS

oseltamivir

RELENZA

§ MISCELLANEOUS

clindamycin

ivermectin

linezolid

metronidazole

nitrofurantoin

sulfamethoxazole-

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit www.caremark.com or contact a CVS Caremark Customer Care representative.

trimethoprim
EMVERM
XIFAXAN 550 MG

ANTINEOPLASTIC AGENTS

HORMONAL ANTINEOPLASTIC AGENTS

§ ANTIANDROGENS
bicalutamide

§ MISCELLANEOUS
VISTOGARD

CARDIOVASCULAR

§ ACE INHIBITORS

fosinopril
lisinopril
quinapril
ramipril

§ ACE INHIBITOR / DIURETIC COMBINATIONS

fosinopril-hydrochlorothiazide
lisinopril-hydrochlorothiazide
quinapril-hydrochlorothiazide

§ ANGIOTENSIN II RECEPTOR ANTAGONISTS / DIURETIC COMBINATIONS

candesartan / candesartan-hydrochlorothiazide
eprosartan
irbesartan / irbesartan-hydrochlorothiazide
losartan / losartan-hydrochlorothiazide
olmesartan / olmesartan-hydrochlorothiazide
telmisartan / telmisartan-hydrochlorothiazide
valsartan / valsartan-hydrochlorothiazide

§ ANGIOTENSIN II RECEPTOR ANTAGONIST / CALCIUM CHANNEL BLOCKER COMBINATIONS

amlodipine-olmesartan
amlodipine-telmisartan
amlodipine-valsartan

§ ANGIOTENSIN II RECEPTOR ANTAGONIST / CALCIUM CHANNEL BLOCKER / DIURETIC COMBINATIONS

amlodipine-valsartan-hydrochlorothiazide
olmesartan-amlodipine-hydrochlorothiazide

§ ANTIARRHYTHMICS

sotalol
MULTAQ

ANTIPEMICS

§ BILE ACID RESINS
cholestyramine

colesevelam

§ CHOLESTEROL ABSORPTION INHIBITORS ezetimibe

§ FIBRATES

fenofibrate
fenofibric acid

§ HMG-CoA REDUCTASE INHIBITORS / COMBINATIONS

atorvastatin
ezetimibe-simvastatin
fluvastatin
lovastatin
pravastatin
rosuvastatin
simvastatin

§ NIACINS

niacin ext-rel

§ OMEGA-3 FATTY ACIDS

omega-3 acid ethyl esters
VASCEPA

§ BETA-BLOCKERS

atenolol
carvedilol
metoprolol succinate ext-rel
metoprolol tartrate
nadolol
pindolol
propranolol
propranolol ext-rel
BYSTOLIC
COREG CR

§ CALCIUM CHANNEL BLOCKERS

amlodipine
diltiazem ext-rel²
nifedipine ext-rel
verapamil ext-rel

§ CALCIUM CHANNEL BLOCKER / ANTIPEMICS COMBINATIONS

amlodipine-atorvastatin

§ DIGITALIS GLYCOSIDES

digoxin

DIRECT RENIN INHIBITORS / DIURETIC COMBINATIONS

TEKTURNA /
TEKTURNA HCT

§ DIURETICS

amiloride
furosemide
hydrochlorothiazide
metolazone
spironolactone-hydrochlorothiazide
torsemide
triamterene-hydrochlorothiazide

HEART FAILURE

BIDIL
CORLANOR
ENTRESTO

§ NITRATES

nitroglycerin lingual spray
nitroglycerin sublingual

§ MISCELLANEOUS RANEXA

CENTRAL NERVOUS SYSTEM

§ ANTICONVULSANTS

carbamazepine
carbamazepine ext-rel
diazepam rectal gel
divalproex sodium
divalproex sodium ext-rel
ethosuximide
gabapentin
lamotrigine
lamotrigine ext-rel
levetiracetam
levetiracetam ext-rel
oxcarbazepine
phenobarbital
phenytoin
phenytoin sodium extended
primidone
tiagabine
topiramate
valproic acid
zonisamide
FYCOMPA
OXTELLAR XR
TROKENDI XR
VIMPAT

§ ANTIDEMENTIA

donepezil
galantamine
galantamine ext-rel
memantine
rivastigmine
rivastigmine transdermal
NAMZARIC

ANTIDEPRESSANTS

§ SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)

citalopram
escitalopram
fluoxetine
paroxetine HCl
paroxetine HCl ext-rel
sertraline
TRINTELLIX
VIIBRYD

§ SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)

desvenlafaxine ext-rel
duloxetine
venlafaxine
venlafaxine ext-rel capsule

§ MISCELLANEOUS AGENTS

bupropion
bupropion ext-rel
mirtazapine
trazodone

§ ANTIPARKINSONIAN AGENTS

amantadine
carbidopa-levodopa
carbidopa-levodopa ext-rel
carbidopa-levodopa-entacapone
entacapone
pramipexole
pramipexole ext-rel
rasagiline
ropinirole
ropinirole ext-rel
selegiline
NEUPRO

ANTIPSYCHOTICS

§ ATYPICALS

aripiprazole
clozapine
olanzapine
quetiapine
quetiapine ext-rel
risperidone
ziprasidone
ABILIFY MAINTENA
ARISTADA
LATUDA
VRAYLAR

§ ATTENTION DEFICIT HYPERACTIVITY DISORDER

amphetamine-dextroamphetamine
mixed salts
amphetamine-dextroamphetamine
mixed salts ext-rel
atomoxetine
guanfacine ext-rel
methylphenidate
methylphenidate ext-rel
MYDAYIS
VYVANSE

FIBROMYALGIA

LYRICA
SAVELLA

HYPNOTICS

§ NONBENZODIAZEPINES

eszopiclone
zolpidem

zolpidem ext-rel
zolpidem sublingual
BELSOMRA

TRICYCLICS SILENOR

MIGRAINE

§ ERGOTAMINE DERIVATIVES
ergotamine-caffeine

§ SELECTIVE SEROTONIN AGONISTS

eletriptan
naratriptan
rizatriptan
sumatriptan
zolmitriptan
ONZETRA XSAIL
ZEMBRACE SYMTOUCH
ZOMIG NASAL SPRAY

SELECTIVE SEROTONIN AGONIST / NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) COMBINATIONS
TREMIMET

§ MUSCULOSKELETAL THERAPY AGENTS

cyclobenzaprine

§ NARCOLEPSY

armodafinil

POSTHERPETIC NEURALGIA (PHN)

GRALISE

PSYCHOTHERAPEUTIC - MISCELLANEOUS

§ OPIOID ANTAGONISTS

naloxone injection
NARCAN NASAL SPRAY

§ PARTIAL OPIOID AGONIST / OPIOID ANTAGONIST COMBINATIONS

buprenorphine-naloxone
sublingual tablet
SUBOXONE FILM
ZUBSOLV

PSEUDOBULBAR AFFECT AGENTS

NUEDEXTA

§ VASOMOTOR SYMPTOM AGENTS

paroxetine mesylate

ENDOCRINE AND METABOLIC

§ ANDROGENS

testosterone gel
testosterone solution
ANDRODERM
ANDROGEL 1.62%

ANTIDIABETICS
AMYLIN ANALOGS
SYMLINPEN

§ BIGUANIDES
metformin
metformin ext-rel

§ BIGUANIDE /
SULFONYLUREA
COMBINATIONS
glipizide-metformin

DIPEPTIDYL PEPTIDASE-4
(DPP-4) INHIBITORS
JANUVIA

DIPEPTIDYL PEPTIDASE-4
(DPP-4) INHIBITOR /
BIGUANIDE COMBINATIONS
JANUMET
JANUMET XR

INCRETIN MIMETIC AGENTS
OZEMPIC
TRULICITY
VICTOZA

INCRETIN MIMETIC AGENT /
INSULIN COMBINATIONS
SOLIQUA

INSULINS
BASAGLAR
FIASP
HUMULIN R U-500
LEVEMIR
NOVOLIN 70/30
NOVOLIN N
NOVOLIN R
NOVOLOG
NOVOLOG MIX 70/30
TRESIBA

§ INSULIN SENSITIZERS
pioglitazone

§ INSULIN SENSITIZER /
BIGUANIDE COMBINATIONS
pioglitazone-metformin

§ INSULIN SENSITIZER /
SULFONYLUREA
COMBINATIONS
pioglitazone-glimepiride

§ MEGLITINIDES
nateglinide
repaglinide

SODIUM-GLUCOSE
CO-TRANSPORTER 2
(SGLT2) INHIBITORS
FARXIGA
JARDIANCE

SODIUM-GLUCOSE
CO-TRANSPORTER 2
(SGLT2) INHIBITOR /
BIGUANIDE COMBINATIONS
SYNJARDY

SYNJARDY XR
XIGDUO XR

SODIUM-GLUCOSE
CO-TRANSPORTER 2
(SGLT2) INHIBITOR /
DIPEPTIDYL PEPTIDASE-4
(DPP-4) INHIBITOR
COMBINATIONS
GLYXAMBI
QTERN

§ SULFONYLUREAS
glimepiride
glipizide
glipizide ext-rel

SUPPLIES
ACCU-CHEK AVIVA PLUS
STRIPS AND KITS³
ACCU-CHEK COMPACT
PLUS STRIPS AND KITS³
ACCU-CHEK GUIDE
STRIPS AND KITS³
ACCU-CHEK SMARTVIEW
STRIPS AND KITS³
BD ULTRAFINE INSULIN
SYRINGES AND
NEEDLES

CALCIUM REGULATORS
§ BISPHOSPHONATES
alendronate
ibandronate
risedronate

§ CALCITONINS
calcitonin-salmon

§ CARNITINE DEFICIENCY
AGENTS
levocarnitine

CONTRACEPTIVES
§ MONOPHASIC

*ethinyl estradiol-
drospirenone*
*ethinyl estradiol-
drospirenone-levomefolate*
*ethinyl estradiol-
norethindrone acetate*
*ethinyl estradiol-
norethindrone acetate-iron*
SAFYRAL

§ BIPHASIC
LO LOESTRIN FE

§ TRIPHASIC
ethinyl estradiol-norgestimate

FOUR PHASE
NATAZIA

§ EXTENDED CYCLE
*ethinyl estradiol-
levonorgestrel*

§ TRANSDERMAL
*ethinyl estradiol-
norelgestromin*

VAGINAL
NUVARING

ESTROGENS
§ ORAL
estradiol
estropipate
PREMARIN

§ TRANSDERMAL
estradiol
DIVIGEL
EVAMIST
MINIVELLE

§ VAGINAL
estradiol
ESTRACE CREAM
ESTRING
PREMARIN CREAM

ESTROGEN / PROGESTINS
§ ORAL
estradiol-norethindrone
PREMPHASE
PREMPRO

TRANSDERMAL
CLIMARA PRO
COMBIPATCH

ESTROGEN / SELECTIVE
ESTROGEN RECEPTOR
MODULATOR
COMBINATIONS
DUAVEE

§ GLUCOCORTICOIDS
dexamethasone
methylprednisolone
prednisolone solution
prednisone

GLUCOSE ELEVATING
AGENTS
GLUCAGEN HYPOKIT
GLUCAGON EMERGENCY
KIT

§ PHOSPHATE BINDER
AGENTS
calcium acetate
lanthanum carbonate
sevelamer carbonate
PHOSLYRA
VELPHORO

POTASSIUM-REMOVING
AGENTS
VELTASSA

PROGESTINS
§ ORAL
medroxyprogesterone
megestrol acetate
progesterone, micronized

VAGINAL
CRINONE
ENDOMETRIN

§ SELECTIVE ESTROGEN
RECEPTOR MODULATORS
raloxifene
OSPHENA

§ THYROID SUPPLEMENTS
levothyroxine
SYNTHROID

GASTROINTESTINAL

§ ANTIEMETICS
dronabinol
granisetron
meclizine
metoclopramide
ondansetron
prochlorperazine
promethazine
trimethobenzamide
DICLEGIS
SANCUSO
VARUBI

§ H₂ RECEPTOR
ANTAGONISTS
ranitidine

INFLAMMATORY BOWEL
DISEASE

§ ORAL AGENTS
balsalazide
budesonide capsule
sulfasalazine
sulfasalazine delayed-rel
APRISO
LIALDA
PENTASA
UCERIS

§ RECTAL AGENTS
hydrocortisone enema
*mesalamine rectal
suspension*
CANASA
CORTIFOAM

§ IRRITABLE BOWEL
SYNDROME
alosetron
AMITIZA
LINZESS
VIBERZI

§ LAXATIVES
lactulose
peg 3350-electrolytes
SUPREP

OPIOID-INDUCED
CONSTIPATION
MOVANTIK

PANCREATIC ENZYMES
CREON
VIOKACE

ZENPEP

§ PROTON PUMP
INHIBITORS
esomeprazole
lansoprazole
omeprazole
 pantoprazole
DEXILANT

§ STEROIDS, RECTAL
PROCTOFOAM-HC

§ ULCER THERAPY
COMBINATIONS
PYLERA

GENITOURINARY

§ BENIGN PROSTATIC
HYPERPLASIA
alfuzosin ext-rel
doxazosin
dutasteride
dutasteride-tamsulosin
finasteride
tamsulosin
terazosin
RAPAFLO

§ URINARY
ANTISPASMODICS
darifenacin ext-rel
oxybutynin
oxybutynin ext-rel
tolterodine
tolterodine ext-rel
trospium
trospium ext-rel
MYRBETRIQ
TOVIAZ
VESICARE

HEMATOLOGIC

§ ANTICOAGULANTS
warfarin
ELIQUIS
XARELTO

§ PLATELET AGGREGATION
INHIBITORS
clopidogrel
dipyridamole ext-rel-aspirin
prasugrel
BRILINTA

IMMUNOLOGIC AGENTS

ALLERGENIC EXTRACTS
GRASTEK
RAGWITEK

NUTRITIONAL / SUPPLEMENTS

§ ELECTROLYTES
potassium chloride liquid

VITAMINS AND MINERALS**§ PRENATAL VITAMINS**

prenatal vitamins
CITRANATAL

RESPIRATORY**§ ANAPHYLAXIS TREATMENT AGENTS**

epinephrine auto-injector
EPIPEN
EPIPEN JR

§ ANTICHOLINERGICS

ipratropium inhalation solution
INCRUSE ELLIPTA
SPIRIVA

ANTICHOLINERGIC / BETA AGONIST COMBINATIONS**§ SHORT ACTING**

ipratropium-albuterol inhalation solution
COMBIVENT RESPIMAT

LONG ACTING

ANORO ELLIPTA
BEVESPI AEROSPHERE
STIOLTO RESPIMAT

ANTICHOLINERGIC / BETA AGONIST / STEROID INHALANT COMBINATIONS

TRELEGY ELLIPTA

BETA AGONISTS, INHALANTS**§ SHORT ACTING**

albuterol inhalation solution
levalbuterol tartrate CFC-free aerosol
PROAIR HFA
PROAIR RESPICLICK

LONG ACTING**Hand-held Active Inhalation**

SEREVENT
STRIVERDI RESPIMAT

Nebulized Passive Inhalation

PERFORMIST

§ LEUKOTRIENE MODULATORS

montelukast
zafirlukast
zileuton ext-rel

§ NASAL ANTIHISTAMINES

azelastine
olopatadine

§ NASAL STEROIDS / COMBINATIONS

flunisolide
fluticasone
mometasone
triamcinolone
DYMISTA

PHOSPHODIESTERASE-4 INHIBITORS

DALIRESP

STEROID / BETA AGONIST COMBINATIONS

ADVAIR
BREQ ELLIPTA
SYMBICORT

§ STEROID INHALANTS

budesonide inhalation suspension
ARNUITY ELLIPTA
ASMANEX
FLOVENT DISKUS
FLOVENT HFA
PULMICORT FLEXHALER
QVAR
QVAR REDIHALER

TOPICAL**DERMATOLOGY****ACNE****§ Topical**

adapalene
benzoyl peroxide
clindamycin solution
clindamycin-benzoyl peroxide
erythromycin solution
erythromycin-benzoyl peroxide
tretinoin
ATRALIN
DIFFERIN

EPIDUO
RETIN-A MICRO
TAZORAC

§ ACTINIC KERATOSIS

fluorouracil cream 5%
fluorouracil solution
imiquimod
PICATO
TOLAK
ZYCLARA

§ ANTIFUNGALS

ciclopirox
clotrimazole
econazole
ketoconazole
nystatin
JUBLIA
LUZU
NAFTIN

§ ANTIPSORIATICS

acitretin
calcipotriene
methoxsalen

§ ATOPIC DERMATITIS

tacrolimus
ELIDEL
EUCRISA

CORTICOSTEROIDS**§ Low Potency**

desonide
hydrocortisone

§ Medium Potency

clocortolone
hydrocortisone butyrate
mometasone
triamcinolone

§ High Potency

desoximetasone
fluocinonide

§ Very High Potency

clobetasol cream, foam, gel, lotion, ointment, shampoo

§ ROSACEA

metronidazole
FINACEA
ORACEA

SOOLANTRA

MOUTH / THROAT / DENTAL AGENTS**PROTECTANTS**

EPISIL

OPHTHALMIC**§ ANTIALLERGICS**

azelastine
cromolyn sodium
olopatadine
LASTACAPT
PAZEO

§ ANTI-INFECTIVES

ciprofloxacin
erythromycin
gentamicin
levofloxacin
moxifloxacin
ofloxacin
sulfacetamide
tobramycin
BESIVANCE
CILOXAN OINTMENT
MOXEZA

§ ANTI-INFECTIVE / ANTI-INFLAMMATORY COMBINATIONS

neomycin-polymyxin B-bacitracin-hydrocortisone
neomycin-polymyxin B-dexamethasone
tobramycin-dexamethasone
TOBRADEX OINTMENT
TOBRADEX ST
ZYLET

ANTI-INFLAMMATORIES**§ Nonsteroidal**

brufenac
diclofenac
ketorolac
ACUVAIL
ILEVRO
NEVANAC

§ Steroidal

dexamethasone
prednisolone acetate 1%
DUREZOL
FLAREX

FML FORTE
FML S.O.P.
MAXIDEX
PRED MILD

BETA-BLOCKERS**§ Nonselective**

timolol maleate solution
BETIMOL

Selective

BETOPTIC S

§ CARBONIC ANHYDRASE INHIBITORS

dorzolamide
AZOPT

§ CARBONIC ANHYDRASE INHIBITOR / BETA-BLOCKER COMBINATIONS

dorzolamide-timolol

CARBONIC ANHYDRASE INHIBITOR / SYMPATHOMIMETIC COMBINATIONS

SIMBRINZA

DRY EYE DISEASE

RESTASIS
XIIDRA

§ PROSTAGLANDINS

latanoprost
LUMIGAN
TRAVATAN Z

RHO KINASE INHIBITORS

RHOPRESSA

§ SYMPATHOMIMETICS

brimonidine
ALPHAGAN P

SYMPATHOMIMETIC / BETA-BLOCKER COMBINATIONS

COMBIGAN

OTIC**§ ANTI-INFECTIVE / ANTI-INFLAMMATORY COMBINATIONS**

CIPRODEX

QUICK REFERENCE DRUG LIST**A**

ABILIFY MAINTENA
ABSTRAL
ACCU-CHEK AVIVA PLUS STRIPS AND KITS³
ACCU-CHEK COMPACT PLUS STRIPS AND KITS³
ACCU-CHEK GUIDE STRIPS AND KITS³
ACCU-CHEK SMARTVIEW STRIPS AND KITS³

acitretin
ACUVAIL
acyclovir
adapalene
ADVAIR
albuterol inhalation solution
alendronate
alfuzosin ext-rel
allopurinol
alosetron
ALPHAGAN P

amantadine
amiloride
AMITIZA
amlodipine
amlodipine-atorvastatin
amlodipine-olmesartan
amlodipine-telmisartan
amlodipine-valsartan
amlodipine-valsartan-hydrochlorothiazide
amoxicillin

amoxicillin-clavulanate
amphetamine-dextroamphetamine mixed salts
amphetamine-dextroamphetamine mixed salts ext-rel
ANDRODERM
ANDROGEL 1.62%
ANORO ELLIPTA
APRISO

aripiprazole
ARISTADA
armodafinil
ARNUITY ELLIPTA
ASMANEX
atenolol
atomoxetine
atorvastatin
ATRALIN
azelastine
azithromycin

AZOPT

B

balsalazide
BASAGLAR
BD ULTRAFINE INSULIN
SYRINGES AND
NEEDLES
BELBUCA
BELSOMRA
benzoyl peroxide
BESIVANCE
BETIMOL
BETOPTIC S
BEVESPI AEROSPHERE
bicalutamide
BIDIL
BREO ELLIPTA
BRILINTA
brimonidine
bromfenac
budesonide capsule
budesonide inhalation
suspension
buprenorphine-naloxone
sublingual tablet
bupropion
bupropion ext-rel
BUTRANS
BYSTOLIC

C

calcipotriene
calcitonin-salmon
calcium acetate
CANASA
candesartan
candesartan-
hydrochlorothiazide
carbamazepine
carbamazepine ext-rel
carbidopa-levodopa
carbidopa-levodopa ext-rel
carbidopa-levodopa-
entacapone
carvedilol
cefdinir
cefprozil
cefuroxime axetil
celecoxib
cephalexin
cholestyramine
ciclopirox
CILOXAN OINTMENT
CIPRODEX
ciprofloxacin
ciprofloxacin ext-rel
citalopram
CITRANATAL
clarithromycin
clarithromycin ext-rel
CLIMARA PRO
clindamycin
clindamycin solution
clindamycin-benzoyl
peroxide
clobetasol cream, foam, gel,
lotion, ointment, shampoo
clocortolone

clopidogrel
clotrimazole
clozapine
codeine-acetaminophen
colchicine tablet
COLCRYS
colesevelam
COMBIGAN
COMBIPATCH
COMBIVENT RESPIMAT
COREG CR
CORLANOR
CORTIFOAM
CREON
CRINONE
cromolyn sodium
cyclobenzaprine

D

DALIRESP
darifenacin ext-rel
desonide
desoximetasone
desvenlafaxine ext-rel
dexamethasone
DEXILANT
diazepam rectal gel
DICLEGIS
diclofenac
diclofenac sodium
diclofenac sodium gel 1%
diclofenac sodium solution
diclofenac sodium-
misoprostol
dicloxacillin
DIFFERIN
DIFICID
digoxin
diltiazem ext-rel²
dipyridamole ext-rel-aspirin
divalproex sodium
divalproex sodium ext-rel
DIVIGEL
donepezil
dorzolamide
dorzolamide-timolol
doxazosin
doxycycline hyclate
dronabinol
DUAVEE
duloxetine
DUREZOL
dutasteride
dutasteride-tamsulosin
DYMISTA

E

econazole
eletriptan
ELIDEL
ELIQUIS
EMBEDA
EMVERM
ENDOMETRIN
entacapone
ENTRESTO
EPIDUO
epinephrine auto-injector
EPIPEN

EPIPEN JR
EPISIL
eprosartan
ergotamine-caffeine
erythromycin
erythromycin solution
erythromycin-benzoyl
peroxide
erythromycins
escitalopram
esomeprazole
ESTRACE CREAM
estradiol
estradiol-norethindrone
ESTRING

H

HUMULIN R U-500
hydrochlorothiazide
hydrocodone-acetaminophen
hydrocortisone
hydrocortisone butyrate
hydrocortisone enema
hydromorphone
hydromorphone ext-rel
HYSINGLA ER

ibandronate
ILEVRO
imiquimod
INCRUSE ELLIPTA
ipratropium inhalation
solution
ipratropium-albuterol
inhalation solution
irbesartan
irbesartan-
hydrochlorothiazide
itraconazole
ivermectin

F

FARXIGA
fenofibrate
fenofibric acid
fentanyl transdermal
fentanyl transmucosal
lozenge
FIASP
FINACEA
finasteride
FLAREX
FLOVENT DISKUS
FLOVENT HFA
fluconazole
flunisolide
fluocinonide
fluorouracil cream 5%
fluorouracil solution
fluoxetine
fluticasone
fluvastatin
FML FORTE
FML S.O.P.
fosinopril
fosinopril-hydrochlorothiazide
furosemide
FYCOMPA

G

gabapentin
galantamine
galantamine ext-rel
gentamicin

glimepiride
glipizide
glipizide ext-rel
glipizide-metformin
GLUCAGEN HYPOKIT
GLUCAGON EMERGENCY
KIT
GLYXAMBI
GRALISE
granisetron
GRASTEK
guanfacine ext-rel

I

HUMULIN R U-500
hydrochlorothiazide
hydrocodone-acetaminophen
hydrocortisone
hydrocortisone butyrate
hydrocortisone enema
hydromorphone
hydromorphone ext-rel
HYSINGLA ER

ibandronate
ILEVRO
imiquimod
INCRUSE ELLIPTA
ipratropium inhalation
solution
ipratropium-albuterol
inhalation solution
irbesartan
irbesartan-
hydrochlorothiazide
itraconazole
ivermectin

J

JANUMET
JANUMET XR
JANUVIA
JARDIANCE
JUBLIA

K

ketoconazole
ketorolac

L

lactulose
lamotrigine
lamotrigine ext-rel
lansoprazole
lanthanum carbonate
LASTACFT
latanoprost
LATUDA
levalbuterol tartrate CFC-free
aerosol
LEVEMIR
levetiracetam
levetiracetam ext-rel
levocarnitine
levofloxacin
levothyroxine
LIALDA
linezolid

LINZESS
lisinopril
lisinopril-hydrochlorothiazide
LO LOESTRIN FE
losartan
losartan-hydrochlorothiazide
lovastatin
LUMIGAN
LUZU
LYRICA

M

MAXIDEX
meclizine
medroxyprogesterone
megestrol acetate
meloxicam
memantine
mesalamine rectal
suspension
metformin
metformin ext-rel
methadone
methoxsalen
methylphenidate
methylphenidate ext-rel
methylprednisolone
metoclopramide
metolazone
metoprolol succinate ext-rel
metoprolol tartrate
metronidazole
MINIVELLE
minocycline
mirtazapine
mometasone
montelukast
morphine
morphine ext-rel
morphine suppository
MOVANTIK
MOXEZA
moxifloxacin
MULTAQ
MYDAYIS
MYRBETRIQ

N

nadolol
NAFTIN
naloxone injection
NAMZARIC
naproxen
naratriptan
NARCAN NASAL SPRAY
NATAZIA
nateglinide
neomycin-polymyxin B-
bacitracin-hydrocortisone
neomycin-polymyxin B-
dexamethasone
NEUPRO
NEVANAC
niacin ext-rel
nifedipine ext-rel
nitrofurantoin
nitroglycerin lingual spray
nitroglycerin sublingual
NOVOLIN 70/30

NOVOLIN N
NOVOLIN R
NOVOLOG
NOVOLOG MIX 70/30
NUCYNTA
NUCYNTA ER
NUEDEXTA
NUVARING
nystatin

O
ofloxacin
olanzapine
olmesartan
olmesartan-amlodipine-
hydrochlorothiazide
olmesartan-
hydrochlorothiazide
olopatadine
omega-3 acid ethyl esters
omeprazole
ondansetron
ONZETRA XSAIL
ORACEA
oseltamivir
OSPHENA
oxcarbazepine
OXTELLAR XR
oxybutynin
oxybutynin ext-rel
oxycodone
oxycodone-acetaminophen
OXYCONTIN
OZEMPIC

P
pantoprazole
paroxetine HCl
paroxetine HCl ext-rel
paroxetine mesylate
PAZEO
peg 3350-electrolytes
penicillin VK
PENTASA
PERFOROMIST
phenobarbital
phenytoin
phenytoin sodium extended
PHOSLYRA

PICATO
pindolol
pioglitazone
pioglitazone-glimepiride
pioglitazone-metformin
potassium chloride liquid
pramipexole
pramipexole ext-rel
prasugrel
pravastatin
PRED MILD
prednisolone acetate 1%
prednisolone solution
prednisone
PREMARIN
PREMARIN CREAM
PREMPHASE
PREMPRO
prenatal vitamins
primidone
PROAIR HFA
PROAIR RESPICLICK
probenecid
prochlorperazine
PROCTOFOAM-HC
progesterone, micronized
promethazine
propranolol
propranolol ext-rel
PULMICORT FLEXHALER
PYLERA

Q
QTERN
quetiapine
quetiapine ext-rel
quinapril
quinapril-hydrochlorothiazide
QVAR
QVAR REDIHALER

R
RAGWITEK
raloxifene
ramipril
RANEXA
ranitidine
RAPAFLO
rasagiline

RELENZA
repaglinide
RESTASIS
RETIN-A MICRO
RHOPRESSA
risedronate
risperidone
rivastigmine
rivastigmine transdermal
rizatriptan
ropinirole
ropinirole ext-rel
rosuvastatin

S
SAFYRAL
SANCUSO
SAVELLA
selegiline
SEREVENT
sertraline
sevelamer carbonate
SILENOR
SIMBRINZA
simvastatin
SOLIQUA
SOOLANTRA
sotalol
SPIRIVA
spironolactone-
hydrochlorothiazide
STIOLTO RESPIMAT
STRIVERDI RESPIMAT
SUBOXONE FILM
SUBSYS
sulfacetamide
sulfamethoxazole-
trimethoprim
sulfasalazine
sulfasalazine delayed-rel
sumatriptan
SUPRAX
SUPREP
SYMBICORT
SYMLINPEN
SYNJARDY
SYNJARDY XR
SYNTHROID

T
tacrolimus
tamsulosin
TAZORAC
TEKTRUNA
TEKTRUNA HCT
telmisartan
telmisartan-
hydrochlorothiazide
terazosin
terbinafine tablet
testosterone gel
testosterone solution
tetracycline
tiagabine
timolol maleate solution
TOBRADEX OINTMENT
TOBRADEX ST
tobramycin
tobramycin-dexamethasone
TOLAK
tolterodine
tolterodine ext-rel
topiramate
toremide
TOVIAZ
tramadol
tramadol ext-rel
TRAVATAN Z
trazodone
TRELEGY ELLIPTA
TRESIBA
tretinoin
TREMIMET
triamcinolone
triamterene-
hydrochlorothiazide
trimethobenzamide
TRINTELLIX
TROKENDI XR
trospium
trospium ext-rel
TRULICITY

U
UCERIS
ULORIC

V
valacyclovir
valganciclovir
valproic acid
valsartan
valsartan-hydrochlorothiazide
VARUBI
VASCEPA
VELPHORO
VELTASSA
venlafaxine
venlafaxine ext-rel capsule
verapamil ext-rel
VESICARE
VIBERZI
VICTOZA
VIIBRYD
VIMPAT
VIOKACE
VISTOGARD
VRAYLAR
VYVANSE

W
warfarin

X
XARELTO
XIFAXAN 550 MG
XIGDUO XR
XIIDRA

Z
zafirlukast
ZEMBRACE SYMTOUCH
ZENPEP
zileuton ext-rel
ziprasidone
zolmitriptan
zolpidem
zolpidem ext-rel
zolpidem sublingual
ZOMIG NASAL SPRAY
zonisamide
ZUBSOLV
ZYCLARA
ZYLET

PREFERRED OPTIONS LIST

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
ABILIFY	aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, LATUDA, VRAYLAR	ALEVICYN GEL, ALEVICYN KIT, ALEVICYN SG, Alevicyn solution	desonide, hydrocortisone
ACANYA	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	ALLISON MEDICAL INSULIN SYRINGES ⁵	BD ULTRAFINE INSULIN SYRINGES
ACTICLATE	doxycycline hyclate	ALORA	estradiol, DIVIGEL, EVAMIST, MINIVELLE
ACTOS	pioglitazone	ALTOPREV	atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
ADDERALL XR	amphetamine-dextroamphetamine mixed salts ext-rel, methylphenidate ext-rel, MYDAYIS, VYVANSE	ALVESCO	ARNUITY ELLIPTA, ASMANEX, FLOVENT DISKUS, FLOVENT HFA, PULMICORT FLEXHALER, QVAR, QVAR REDIHALER
ALCORTIN A	desonide, hydrocortisone	AMRIX	cyclobenzaprine
		ANDROGEL 1%	testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit www.caremark.com or contact a CVS Caremark Customer Care representative.



DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
ANGELIQ	estradiol/norethindrone, PREMPHASE, PREMPRO	CAFERGOT	eletriptan, ergotamine-caffeine, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY
ANTARA	fenofibrate, fenofibric acid	CAMBIA	diclofenac sodium, meloxicam, naproxen
APEXICON E	desoximetasone, fluocinonide	CARAC	fluorouracil cream 5%, fluorouracil solution, imiquimod, PICATO, TOLAK, ZYCLARA
APIDRA	FIASP, NOVOLOG	CARDIZEM	diltiazem ext-rel (except generic CARDIZEM LA)
ARMOUR THYROID	levothyroxine, SYNTHROID	CARDIZEM CD	diltiazem ext-rel (except generic CARDIZEM LA)
ARTHROTEC	celecoxib; diclofenac sodium, meloxicam or naproxen WITH esomeprazole, lansoprazole, omeprazole, pantoprazole or DEXILANT	CARDIZEM LA (and its generics)	diltiazem ext-rel (except generic CARDIZEM LA)
ASACOL HD	balsalazide, sulfasalazine, sulfasalazine delayed-rel, APRISO, LIALDA, PENTASA	CARNITOR	levocarnitine
ASCENSIA STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3	CARNITOR SF	levocarnitine
ATACAND, ATACAND HCT	candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide	CLINDAGEL	erythromycin solution
ATROVENT HFA	ipratropium inhalation solution, INCRUSE ELLIPTA, SPIRIVA	clobetasol spray	clobetasol foam
AVENOVA	Consult doctor	CLOBEX SPRAY	clobetasol foam
AXERT	eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY	COLAZAL	balsalazide
AZELEX	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	CONTOUR NEXT STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3
BECONASE AQ	flunisolide, fluticasone, mometasone, triamcinolone, DYMISTA	CONTOUR STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3
BENICAR, BENICAR HCT	candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide	CRESTOR	atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
BENSAL HP	desonide, hydrocortisone	CYMBALTA	desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule
BENZAC AC	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	DELZICOL	balsalazide, sulfasalazine, sulfasalazine delayed-rel, APRISO, LIALDA, PENTASA
BENZACLIN	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	DETROL LA	darifenacin ext-rel, oxybutynin ext-rel, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, MYRBETRIQ, TOVIAZ, VESICARE
BENZIQ	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	DEXPAK	dexamethasone, methylprednisolone, prednisolone solution, prednisone
BETAPACE, BETAPACE AF	sotalol	DIOVAN, DIOVAN HCT	candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide
BREEZE 2 STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3	DORAL	eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR
butalbital-acetaminophen-caffeine capsule	diclofenac sodium, naproxen	DORYX	doxycycline hyclate
BYDUREON	OZEMPIC, TRULICITY, VICTOZA	DORYX MPC	doxycycline hyclate
BYETTA	OZEMPIC, TRULICITY, VICTOZA	DULERA	ADVAIR, BREO ELLIPTA, SYMBICORT
		DUTOPROL	metoprolol succinate ext-rel WITH hydrochlorothiazide
		DYRENIUM	amiloride
		EDARBI, EDARBYCLOR	candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide
		EDLUAR	eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR
		E.E.S. GRANULES	erythromycins

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit www.caremark.com or contact a CVS Caremark Customer Care representative.

HealthChoice

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
EFFEXOR XR	<i>desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule</i>	ISTALOL	<i>timolol maleate solution, BETIMOL</i>
ENABLEX	<i>darifenacin ext-rel, oxybutynin ext-rel, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, MYRBETRIQ, TOVIAZ, VESICARE</i>	JALYN	<i>dutasteride-tamsulosin; dutasteride or finasteride WITH alfuzosin ext-rel, doxazosin, tamsulosin, terazosin, RAPAFLO</i>
ERYPED	<i>erythromycins</i>	JENTADUETO	JANUMET, JANUMET XR
EVZIO	<i>naloxone injection, NARCAN NASAL SPRAY</i>	JENTADUETO XR	JANUMET, JANUMET XR
EXFORGE	<i>amlodipine-olmesartan, amlodipine-telmisartan, amlodipine-valsartan</i>	KAZANO	JANUMET, JANUMET XR
EXFORGE HCT	<i>amlodipine-valsartan-hydrochlorothiazide, olmesartan-amlodipine-hydrochlorothiazide</i>	KOMBIGLYZE XR	JANUMET, JANUMET XR
FANAPT	<i>aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, LATUDA, VRAYLAR</i>	LANOXIN TABLET (125 MCG and 250 MCG only)	<i>digoxin</i>
FEMRING	<i>estradiol, ESTRACE CREAM, ESTRING, PREMARIN CREAM</i>	LANTUS	BASAGLAR, LEVEMIR, TRESIBA
FETZIMA	<i>desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule</i>	LAZANDA	<i>fantanyl transmucosal lozenge, ABSTRAL, SUBSYS</i>
FIORICET CAPSULE	<i>diclofenac sodium, naproxen</i>	LESCOL XL	<i>atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin</i>
<i>fluorouracil cream 0.5%</i>	<i>fluorouracil cream 5%, fluorouracil solution, imiquimod, PICATO, TOLAK, ZYCLARA</i>	<i>levorphanol</i>	<i>fantanyl transdermal, hydromorphone ext-rel, methadone, morphine ext-rel, EMBEDA, HYSINGLA ER, NUCYNTA ER, OXYCONTIN</i>
FORTAMET	<i>metformin, metformin ext-rel</i>	LIPITOR	<i>atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin</i>
FORTESTA	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>	LIVALO	<i>atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin</i>
FOSAMAX PLUS D	<i>alendronate, ibandronate, risedronate</i>	LUNESTA	<i>eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR</i>
FOSRENOL	<i>calcium acetate, lanthanum carbonate, sevelamer carbonate, PHOSLYRA, VELPHORO</i>	MACRODANTIN	<i>nitrofurantoin</i>
FREESTYLE STRIPS AND KITS 4	<i>ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3</i>	<i>Matzim LA</i>	<i>diltiazem ext-rel (except generic CARDIZEM LA)</i>
FROVA	<i>eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY</i>	MENEST	<i>estradiol, estropipate, PREMARIN</i>
GLUMETZA	<i>metformin, metformin ext-rel</i>	MENOSTAR	<i>estradiol</i>
HORIZANT	<i>gabapentin, GRALISE</i>	MIACALCIN INJECTION	<i>alendronate, calcitonin-salmon, ibandronate, risedronate, FORTEO, PROLIA, TYMLOS</i>
HUMALOG	FIASP, NOVOLOG	MIACALCIN NASAL SPRAY	<i>calcitonin-salmon</i>
HUMALOG MIX 50/50	NOVOLOG MIX 70/30	MICARDIS, MICARDIS HCT	<i>candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide</i>
HUMALOG MIX 75/25	NOVOLOG MIX 70/30	MILLIPRED	<i>dexamethasone, methylprednisolone, prednisolone solution, prednisone</i>
HUMULIN 70/30	NOVOLIN 70/30	MINOCIN	<i>minocycline</i>
HUMULIN N	NOVOLIN N	NAPRELAN	<i>diclofenac sodium, meloxicam, naproxen</i>
HUMULIN R	NOVOLIN R	NATESTO	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>
INDOCIN	<i>diclofenac sodium, meloxicam, naproxen</i>	NESINA	JANUVIA
INNOPRAN XL	<i>atenolol, carvedilol, metoprolol succinate ext-rel, metoprolol tartrate, nadolol, pindolol, propranolol, propranolol ext-rel, BYSTOLIC, COREG CR</i>	NEXIUM	<i>esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT</i>
INTERMEZZO	<i>eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR</i>	NILANDRON	<i>bicalutamide, XTANDI, ZYTIGA</i>
INTUNIV	<i>amphetamine-dextroamphetamine mixed salts ext-rel, atomoxetine, guanfacine ext-rel, methylphenidate ext-rel, MYDAYIS, VYVANSE</i>	NITROMIST	<i>nitroglycerin lingual spray, nitroglycerin sublingual</i>
INVOKAMET	SYNJARDY, SYNJARDY XR, XIGDUO XR	NORITATE	<i>metronidazole, FINACEA, SOOLANTRA</i>
INVOKAMET XR	SYNJARDY, SYNJARDY XR, XIGDUO XR	NORVASC	<i>amlodipine</i>
INVOKANA	FARXIGA, JARDIANCE	NOVACORT	<i>desonide, hydrocortisone</i>
		NOVO NORDISK NEEDLES 5	BD ULTRAFINE NEEDLES
		NUVIGIL	<i>armodafinil</i>
		OLEPTRO	<i>trazodone</i>

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit www.caremark.com or contact a CVS Caremark Customer Care representative.

HealthChoice

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
OLUX-E	<i>clobetasol foam</i>	RIOMET	<i>metformin, metformin ext-rel</i>
OMNARIS	<i>flunisolide, fluticasone, mometasone, triamcinolone, DYMISTA</i>	ROZEREM	<i>eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR</i>
ONETOUCH ULTRA STRIPS AND KITS ⁴	ACCU-CHEK AVIVA PLUS STRIPS AND KITS ³ , ACCU-CHEK COMPACT PLUS STRIPS AND KITS ³ , ACCU-CHEK GUIDE STRIPS AND KITS ³ , ACCU-CHEK SMARTVIEW STRIPS AND KITS ³	SEROQUEL XR	<i>aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, LATUDA, VRAYLAR</i>
ONETOUCH VERIO STRIPS AND KITS ⁴	ACCU-CHEK AVIVA PLUS STRIPS AND KITS ³ , ACCU-CHEK COMPACT PLUS STRIPS AND KITS ³ , ACCU-CHEK GUIDE STRIPS AND KITS ³ , ACCU-CHEK SMARTVIEW STRIPS AND KITS ³	SORILUX	<i>calcipotriene</i>
ONEXTON	<i>adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC</i>	SPRIX	<i>diclofenac sodium, meloxicam, naproxen</i>
ONGLYZA	JANUVIA	STRIANT	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>
OSENI	JANUMET, JANUMET XR	SURE-TEST STRIPS AND KITS ⁴	ACCU-CHEK AVIVA PLUS STRIPS AND KITS ³ , ACCU-CHEK COMPACT PLUS STRIPS AND KITS ³ , ACCU-CHEK GUIDE STRIPS AND KITS ³ , ACCU-CHEK SMARTVIEW STRIPS AND KITS ³
OWEN MUMFORD NEEDLES ⁵	BD ULTRAFINE NEEDLES	SYNERDERM	<i>desonide, hydrocortisone</i>
OXYTROL	<i>darifenacin ext-rel, oxybutynin ext-rel, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, MYRBETRIQ, TOVIAZ, VESICARE</i>	TANZEUM	OZEMPIC, TRULICITY, VICTOZA
PANCREAZE	CREON, VIOKACE, ZENPEP	TARGADOX	<i>doxycycline hyclate</i>
PENNSAID	<i>diclofenac sodium, diclofenac sodium gel 1%, diclofenac sodium solution, meloxicam, naproxen</i>	TESTIM	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>
PERRIGO NEEDLES ⁵	BD ULTRAFINE NEEDLES	<i>testosterone gel 1% ⁶</i>	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>
PERTZYE	CREON, VIOKACE, ZENPEP	TIROSINT	<i>levothyroxine, SYNTHROID</i>
PEXEVA	<i>citalopram, escitalopram, fluoxetine, paroxetine HCl, paroxetine HCl ext-rel, sertraline, TRINTELLIX, VIIBRYD</i>	TOUJEO	BASAGLAR, LEVEMIR, TRESIBA
PLAVIX	<i>clopidogrel, prasugrel, BRILINTA</i>	TRADJENTA	JANUVIA
PRADAXA	<i>warfarin, ELIQUIS, XARELTO</i>	TRICOR	<i>fenofibrate, fenofibric acid</i>
PRECISION XTRA STRIPS AND KITS ⁴	ACCU-CHEK AVIVA PLUS STRIPS AND KITS ³ , ACCU-CHEK COMPACT PLUS STRIPS AND KITS ³ , ACCU-CHEK GUIDE STRIPS AND KITS ³ , ACCU-CHEK SMARTVIEW STRIPS AND KITS ³	TRIGLIDE	<i>fenofibrate, fenofibric acid</i>
PRED FORTE	<i>dexamethasone, prednisolone acetate 1%, DUREZOL, FLAREX, FML FORTE, FML S.O.P., MAXIDEX, PRED MILD</i>	TRILIPIX	<i>fenofibrate, fenofibric acid</i>
PREFERAOB	<i>generic prenatal vitamins, CITRANATAL</i>	TRIVIDIA INSULIN SYRINGES ⁵	BD ULTRAFINE INSULIN SYRINGES
PREFEST	<i>estradiol-norethindrone, PREMPHASE, PREMPRO</i>	TRUETEST STRIPS AND KITS ⁴	ACCU-CHEK AVIVA PLUS STRIPS AND KITS ³ , ACCU-CHEK COMPACT PLUS STRIPS AND KITS ³ , ACCU-CHEK GUIDE STRIPS AND KITS ³ , ACCU-CHEK SMARTVIEW STRIPS AND KITS ³
PRENATAL PLUS	<i>generic prenatal vitamins, CITRANATAL</i>	TRUETRACK STRIPS AND KITS ⁴	ACCU-CHEK AVIVA PLUS STRIPS AND KITS ³ , ACCU-CHEK COMPACT PLUS STRIPS AND KITS ³ , ACCU-CHEK GUIDE STRIPS AND KITS ³ , ACCU-CHEK SMARTVIEW STRIPS AND KITS ³
PREVACID	<i>esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT</i>	TUDORZA	INCRUSE ELLIPTA, SPIRIVA
PRIMLEV	<i>hydrocodone-acetaminophen, hydromorphone, morphine, oxycodone-acetaminophen, NUCYNTA</i>	ULTIMED INSULIN SYRINGES ⁵	BD ULTRAFINE INSULIN SYRINGES
PROTONIX	<i>esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT</i>	ULTIMED NEEDLES ⁵	BD ULTRAFINE NEEDLES
PROTOPIC	<i>tacrolimus, ELIDEL, EUCRISA</i>	UROXATRAL	<i>alfuzosin ext-rel, doxazosin, tamsulosin, terazosin, RAPAFLO</i>
PROVENTIL HFA	<i>levalbuterol tartrate CFC-free aerosol, PROAIR HFA, PROAIR RESPICLICK</i>	VALCYTE	<i>valganciclovir</i>
QNASL	<i>flunisolide, fluticasone, mometasone, triamcinolone, DYMISTA</i>	VALTRES	<i>acyclovir, valacyclovir</i>
RAYOS	<i>dexamethasone, methylprednisolone, prednisolone solution, prednisone</i>	VANATOL LQ	<i>diclofenac sodium, naproxen</i>
RELION INSULIN	NOVOLIN INSULIN	VANATOL S	<i>diclofenac sodium, naproxen</i>
RELISTOR	MOVANTI	<i>Vanoxide-HC</i>	<i>adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC</i>
RIMSO-50	Consult doctor	VELTIN	<i>adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC</i>
		<i>venlafaxine ext-rel tablet (except 225 mg)</i>	<i>desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule</i>

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit www.caremark.com or contact a CVS Caremark Customer Care representative.

HealthChoice

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
VENLAFAXINE EXT-REL TABLET (except 225 MG)	<i>desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule</i>	ZIANA	<i>adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC</i>
VENTOLIN HFA	<i>levalbuterol tartrate CFC-free aerosol, PROAIR HFA, PROAIR RESPICLICK</i>	ZOLPIMIST	<i>eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR</i>
VITAFOL-ONE	<i>generic prenatal vitamins, CITRANATAL</i>	ZONEGRAN	<i>carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI XR, VIMPAT</i>
VOGELXO	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>	ZUPLENZ	<i>granisetron, ondansetron, SANCUSO</i>
XOPENEX HFA	<i>levalbuterol tartrate CFC-free aerosol, PROAIR HFA, PROAIR RESPICLICK</i>	ZYFLO, ZYFLO CR	<i>montelukast, zafirlukast, zileuton ext-rel</i>
ZEGERID	<i>esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT</i>		
ZETIA	<i>ezetimibe</i>		
ZETONNA	<i>flunisolide, fluticasone, mometasone, triamcinolone, DYMISTA</i>		

You may be responsible for the full cost of certain non-formulary products that are removed from coverage. Please check with your plan sponsor for more information.

FOR YOUR INFORMATION: Generics should be considered the first line of prescribing. This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. New-to-market products and new variations of products already in the marketplace will not be added to the formulary immediately. Each product will be evaluated for clinical appropriateness and cost-effectiveness. Recommended additions to the formulary will be presented to the CVS Caremark National Pharmacy and Therapeutics Committee (or other appropriate reviewing body) for review and approval. In most instances, a brand-name drug for which a generic product becomes available will be designated as a non-preferred option upon release of the generic product to the market. Specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. The member's prescription benefit plan may have a different copay¹ for specific products on the list. Unless specifically indicated, drug list products will include all dosage forms. This list represents brand products in CAPS, branded generics in upper- and lowercase *italics*, and generic products in lowercase *italics*. Generics listed in therapeutic categories are for representational purposes only. Listed products may be available generically in certain strengths or dosage forms. Dosage forms on this list will be consistent with the category and use where listed. Log in to www.caremark.com to check coverage and copay¹ information for a specific medicine.

An exception process may exist for specific clinical or regulatory circumstances that may require coverage of an excluded medication.

* The preferred options in this list are a broad representation within therapeutic categories of available treatment options and do not necessarily represent clinical equivalency.

§ Generics are available in this class and should be considered the first line of prescribing.

¹ Copayment, copay or coinsurance means the amount a member is required to pay for a prescription in accordance with a Plan, which may be a deductible, a percentage of the prescription price, a fixed amount or other charge, with the balance, if any, paid by a Plan.

² Listing does not include generic CARDIZEM LA.

³ An ACCU-CHEK blood glucose meter may be provided at no charge by the manufacturer to those individuals currently using a meter other than ACCU-CHEK. For more information on how to obtain a blood glucose meter, call: 1-877-418-4746.

⁴ ACCU-CHEK brand test strips are the only preferred options.

⁵ BD ULTRAFINE syringes and needles are the only preferred options.

⁶ Listing reflects the authorized generics for TESTIM and VOGELXO.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. The document is subject to state-specific regulations and rules, including, but not limited to, those regarding generic substitution, controlled substance schedules, preference for brands and mandatory generics whenever applicable.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2018. All rights reserved. 106-1063953-1-010119

www.caremark.com

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit www.caremark.com or contact a CVS Caremark Customer Care representative.

HealthChoice

EXHIBIT C
FILED UNDER SEAL